P506: Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from GermanyECCO'22Year: 2022
Authors: Bokemeyer, B.(1);Picker, N.(2);Kromer, D.(2);Rosin, L.(3);Patel, H.(4);
(1)Gastroenterology Practice, Minden, Minden, Germany;(2)Ingress Health HWM, GmbH, Wismar, Germany;(3)Galapagos Biopharma Deutschland, GmbH, München, Germany;(4)Galapagos, Nv, Mechelen, Belgium;
P507: Need for surgery in patients with ulcerative colitis in the era of biologic therapy.ECCO'22Year: 2022
Authors: Zamora Olaya, J.M.(1);Aparicio-Serrano, A.(1);Gómez Pérez, A.(1);Ortiz Chimbo, D.S.(1);Rodríguez Tirado, M.I.(1);Soto Escribano, P.(1);Marín Pedrosa, S.(1);Iglesias Flores, E.(1);Benítez, J.M.(1);
(1)Reina Sofía University Hospital, Gastroenterology and Hepatology, Córdoba, Spain;IMIBIC
P508: The impact of disease duration and early biologic treatment on transmural healing in Crohn’s diseaseECCO'22Year: 2022
Authors: Revés, J.(1);Freire, G.(2);Sousa, P.(2);Primitivo, A.(2);Nascimento, C.(1);Morão, B.(1);Abreu, N.(3);Palmela, C.(1);Glória, L.(1);Torres, J.(1);
(1)Hospital Beatriz Ângelo, Gastrenterology Department, Loures, Portugal;(2)Hospital Beatriz Ângelo, Radiology Department, Loures, Portugal;(3)Hospital Dr. Nélio Mendonça, Gastrenterology Department, Funchal, Portugal;
P509: Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Sorokina Alexdóttir , M.(1);Bourgonje , A.R.(2);Karsdal , M.A.(1);Bay-Jensen , A.C.(1);Pehrsson , M.(1);Loveikyte , R.(2);van Dullemen , H.M.(2);Visschedijk , M.C.(2); A. M. Festen , E.(2);K. Weersma , R.(2);Faber , K.N.(2);Dijkstra , G.(2);Joachim H. , M.(1);
(1)Nordic Bioscience, Immunoscience, Herlev, Denmark;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;
P510: Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysisECCO'22Year: 2022
Authors: Shehab, M.(1);Alrashed, F.(2);Heron, V.(3);Restellini, S.(4);Bessissow, T.(5);
(1)Mubarak Alkaber University Hospital, Internal medicine, Aljabreyah, Kuwait;(2)Massachusetts College of Pharmacy and Health Sciences, Public health, Boston, United States;(3)University of Montreal, Gastroenterology, Montreal, Canada;(4)University of Geneva, Internal medicine, Geneva, Switzerland;(5)McGill University, Internal medicine, Montreal, Canada;
P511: Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapyECCO'22Year: 2022
Authors: Jijón, M.C.(1);Pujol-Muncunill, G.(1);Lozano Ruf, A.(1);Vila Miravet, V.(1);Alvarez Carnero, L.(1);García Arenas, D.(1);Egea Castillo, N.(1);Martín de Carpi, J.(1);
(1)Hospital Sant Joan de Deu, Paediatric Gastroenterology- Hepatology- and Nutrition, Barcelona, Spain;
P512: Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s diseaseECCO'22Year: 2022
Authors: Kadleckova, B.(1);Podmanicky, D.(2);Lipovska, A.(1);Zelinkova, Z.(1);
(1)St. Michael`s Hospital, Department of Gastroenterology&Digestive Endoscopy, Bratislava, Slovakia;(2)St. Michael`s Hospital, Surgery, Bratislava, Slovakia;
P513: Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.ECCO'22Year: 2022
Authors: Biscanin, A.(1);Tomasic, V.(1);Babic, F.(2);Dorosulic, Z.(1);Kralj, D.(1);Cacic, P.(1);Ogresta, D.(1);Hrabar, D.(1);
(1)University Hospital Centre Sestre Milosrdnice, Department of Internal Medicine, Zagreb, Croatia;(2)Zagreb Emergency Medicine Service, Emergency Medicine, Zagreb, Croatia;
P515: Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapyECCO'22Year: 2022
Authors: Shani, U.(1);Klang, E.(2);Ungar, B.(3);Ben-Horin, S.(3);Kopylov, U.(3);
(1)Tel-HaShomer Sheba Medical Center, Internal Medicine F, Ramat Gan, Israel;(2)Tel-HaShomer Sheba Medical Center, arc, Ramat Gan, Israel;(3)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
P516: Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness studyECCO'22Year: 2022
Authors: Karki, C.(1);Athavale, A.(2);Hantsbarger, G.(3);Lee, K.(4);Milicevic, S.(5);Perovic, M.(6);Raven, L.(7);Sajak-Szczerba, M.(8);Abilash, V.(2);Tozer, P.(9);
(1)Takeda Pharmaceuticals USA Inc., Global Evidence and Outcomes, Cambridge- MA, United States;(2)Trinity Partners- LLC, Insights & Analytics, Waltham- MA, United States;(3)Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States;(4)Crohn's & Colitis Canada, Research & Patient Programs, Toronto, Canada;(5)Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland;(6)European Federation of Crohn’s and Ulcerative Colitis Associations, European Federation of Crohn and Ulcerative Colitis Associations, Brussels, Belgium;(7)Crohn's & Colitis Australia, n/a, Camberwell, Australia;(8)European Federation of Crohn’s and Ulcerative Colitis Associations, n/a, Brussels, Belgium;(9)St. Mark’s Hospital and Academic Institute, Fistula Research Unit, London, United Kingdom;
P517: Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studiesECCO'22Year: 2022
Authors: Vermeire, S.(1);Feagan, B.(2,3);Peyrin-Biroulet, L.(4);Oortwijn, A.(5);Faes, M.(6);de Haas, A.(5);Rogler, G.(7);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Alimentiv, Inc., London Ontario, Canada;(3)London Health Sciences Centre- Western University, Division of Gastroenterology, London Ontario, Canada;(4)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(5)Galapagos, Nv, Leiden, The Netherlands;(6)Galapagos, Nv, Mechelen, Belgium;(7)University Hospital Zurich- University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;
P518: Partial enteral nutrition use for Crohn’s disease management: a systematic reviewECCO'22Year: 2022
Authors: Jatkowska, A.(1);White, B.(1);Gkikas, K.(1);Seenan, J.P.(2);MacDonald, J.(2);Gerasimidis, K.(1);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;
P519: Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Casanova, M.J.(1);Chaparro, M.(1);Nantes, Ó.(2);Varela, P.(3);Vela-González, M.(4);Montserrat, R.(5);Sierra, O.G.(6);Riestra, S.(7);Barreiro-de Acosta, M.(8);Martín-Rodríguez, M.M.(9);Gargallo-Puyuelo, C.J.(10);Reygosa, C.(11);Muñoz, R.(12);García de la Filia-Molina, I.(13);Núñez-Ortiz, A.(14);Kolle, L.(15);Calafat, M.(16);Huguet, J.M.(17);Iglesias-Flores, E.(18);Martínez-Pérez, T.J.(19);Bosch, O.(20);Duque-Alcorta, J.M.(21);Frago-Larramona, S.(22);Sánchez-Azofra, M.(23);Van Domselaar, M.(24);González-Cosano, V.M.(25);Bujanda, L.(26);Rubio, S.(2);Mancebo, A.(3);Castro, B.(5);García-López, S.(6);de Francisco, R.(7);Nieto, L.(8);Laredo, V.(10);Gutiérrez, A.(12);Mesonero, F.(13);Leo-Carnerero, E.(14);Cañete, F.(16);Ruiz, L.(17);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(2)Hospital Universitario de Navarra- Instituto de Investigación Sanitaria de Navarra IdiSNA, Gastroenterology, Pamplona, Spain;(3)Hospital Universitario de Cabueñes, Gastroenterology, Gijón, Spain;(4)Hospital Universitario Nuestra Señora de la Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(5)Hospital Universitario Marqués de Valdecilla- Instituto de Investigación Sanitaria Valdecilla IDIVAL, Gastroenterology, Santander, Spain;(6)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(7)Hospital Universitario Central de Asturias- Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology, Oviedo, Spain;(8)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(9)Hospital Universitario Virgen de las Nieves, Gastroenterology, Granada, Spain;(10)Hospital Clínico Lozano Blesa- Instituto de Investigación Sanitaria Aragón IIS Aragón- and CIBEREHD, Gastroenterology, Zaragoza, Spain;(11)Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain;(12)Hospital General Universitario de Alicante- Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL and CIBEREHD, Gastroenterology, Alicante, Spain;(13)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(14)Hospital Universitario Virgen del Rocío, Gastroenterology, Sevilla, Spain;(15)Hospital General de La Palma, Gastroenterology, Santa Cruz de Tenerife, Spain;(16)Hospital Universitario Germans Trias i Pujol- and CIBEREHD, Gastroenterology, Badalona, Spain;(17)Consorcio Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(18)Hospital Universitario Reina Sofía- Instituto Maimónides de Investigación Biomédica de Córdoba IMIBIC, Gastroenterology, Córdoba, Spain;(19)Hospital Virgen de La Luz, Gastroenterology, Cuenca, Spain;(20)Fundación Jiménez Díaz, Gastroenterology, Madrid, Spain;(21)Hospital Universitario San Agustín, Gastroenterology, Avilés, Spain;(22)Hospital Santa Bárbara, Gastroenterology, Soria, Spain;(23)Hospital Universitario de La Paz, Gastroenterology, Madrid, Spain;(24)Hospital Universitario de Torrejón, Gastroenterology, Madrid, Spain;(25)Hospital de Montilla, Gastroenterology, Córdoba, Spain;(26)Hospital Universitario de Donostia- Instituto Biodonostia- Universidad del País Vasco UPV/EHU- CIBEREHD, Gastroenterology, Donostia, Spain;ADA-SWITCH
P520: Very early intestinal ultrasound predicts intravenous corticosteroid failure in hospitalized severe ulcerative colitis patientsECCO'22Year: 2022
Authors: Fremberg Ilvemark, J.(1);Wilkens, R.(2);Thielsen, P.(1);Kirch Dige, A.(3);Boysen, T.(2);Brynskov, J.(1);Tveiten Bjerrum, J.(1);Seidelin, J.(1);
(1)Herlev University Hospital, Department of Gastroenterology and Hepatology, Copenhagen, Denmark;(2)Hvidovre University Hospital, Gastrounit- Medical Division, Copenhagen, Denmark;(3)Aarhus University Hospital, Department of Gastroenterology and Hepatology, Aarhus, Denmark;
P521: Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trialECCO'22Year: 2022
Authors: Parkes, G.(1);Ungaro, R.(2);Danese, S.(3);Abreu, M.(4);Arenson, E.(5);Zhou, W.(6);Ilo, D.(6);Laroux, F.S.(7);Deng, H.(8);Sanchez Gonzalez, Y.(6);Peyrin-Biroulet, L.(9);
(1)Barts Health NHS Trust- Barts and the London School of Medicine and Dentistry, n/a, London, United Kingdom;(2)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(3)Gastroenterology and Endoscopy IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, n/a, Milano, Italy;(4)Division of Gastroenterology- Crohn's and Colitis Center- University of Miami Miller School of Medicine, n/a, Miami, United States;(5)Adelphi Values, n/a, Boston, United States;(6)AbbVie Inc., n/a, North Chicago, United States;(7)AbbVie Bioresearch Center, n/a, Worcester, United States;(8)AbbVie Inc. and Department of Pharmacy Systems Outcomes and Policy- University of Illinois at Chicago, n/a, Chicago, United States;(9)University Hospital of Nancy- Lorraine University, n/a, Vandoeuvre, France;
P522: Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 ProgramECCO'22Year: 2022
Authors: Peyrin-Biroulet, L.(1);Siegel, C.(2);Tanida, S.(3);Bossuyt, P.(4);Torres, E.(5);Dubinsky, M.(6);Baert, F.(7);Zhou, W.(8);Klaff, J.(8);Berg, S.(8);Laroux, F.S.(9);Sanchez Gonzalez, Y.(8);Yao, X.(8);Zhou, Q.(8);Reinisch, W.(10);
(1)University Hospital of Nancy, none, Vandoeuvre, France;(2)Dartmouth-Hitchcock Medical Center, none, Lebanon, United States;(3)Naogoya City University Hospital, none, Nagoya, Japan;(4)Imelda General Hospital, none, Bonheiden, Belgium;(5)University of Puerto Rico School of Medicine, none, San Juan, United States;(6)Icahn School of Medicine at Mt Sinai, none, New York City, United States;(7)AZ Delta, none, Roeselare-Menen, Belgium;(8)AbbVie- Inc, none, North Chicago, United States;(9)AbbVie Bioresearch Center, none, Worcester, United States;(10)Medical University of Vienna, none, Vienna, Austria;
P523: effectiveness of biological treatments for inflammatory bowel disease in the elderly patientsECCO'22Year: 2022
Authors: Suarez Ferrer, C.J.(1);Mesonero, F.(2);Caballol, B.(3);Ballester, M.P.(4);Baston Rey, I.(5);Castaño Garcia, A.(6);Miranda Bautista, J.(7);Saiz Chumillas, R.(8);Benitez, J.M.(9);Sanchez Delgado, L.(10);Lopez-Garcia, A.(11);Rubin de Celix, C.(12);Martin-Arranz, M.D.(13);Lopez Sanroman, A.(2);Fernandez-Clotet, A.(3);Merino Murgui, V.(14);Calviño Suarez, C.(5);Florez, P.(6);Lobato Matilla, M.E.(7);Sicilia, B.(8);Soto Escribano, P.(15);Maroto Martin, C.(10);Alonso Abreu, I.(16);Melcarne, L.(17);Elena , P.G.(18);Iyo, E.(19);Elosua Gonzalez, A.(20);Saiz, E.(21);Hernandez Villalba, L.(22);Perez Galindo, P.(23);Torrealba Medina , L.(24);Monsalve Alonso , S.(25);Olmos Jerez, J.A.(26);Dueñas Sadornil , C.(27);Barreiro-De Acosta, M.(5);
(1)Hospital Universitario La Paz, Gastroenterology Department. IBD Unit, Madrid, Spain;(2)Ramón y Cajal University Hospital, Gastroenterology, Madrid, Spain;(3)Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Clinico de Valencia, gastroenterology, Valencia, Spain;(5)Hospital Universitario Clínico de Santiago, gastroenterology, Santiago de Compostela, Spain;(6)Hospital Universitario Central de Asturias, gastroenterology, Oviedo, Spain;(7)Hospital Universitario Gregorio Marañon, gastroenterology, Madrid, Spain;(8)Burgos University Hospital-, gastroenterology, Burgos, Spain;(9)Hospital Reina Sofia, gastroenterology, Cordoba, Spain;(10)Hospital Universitario de Valladolid-, gastroenterology, Valladolid, Spain;(11)Hospital del Mar, gastroenterology, Barcelona, Spain;(12)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IISIP., gastroenterology, Madrid, Spain;(13)Gastroenterology Department. School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute forHealth Research- La Paz Hospital, Gastroenterology Department. School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute forHealth Research- La Paz Hospital, Madrid, Spain;(14)Hospital Clinico of Valencia, gastroenterology, Valencia, Spain;(15)Hospital Universitario Reina Sofia, gastroenterology, Cordoba, Spain;(16)Hospital Universitario de Canarias., gastroenterology, Tenerife, Spain;(17)Hospital Universitari Parc Taulli- Sabadel-, gastroenterology, Barcelona, Spain;(18)Hospital Royo Villanova-Zaragoza, Gastroenterology, Zaragoza, Spain;(19)Hospital Comarcal de Inca, Gastroenterology Department-, Baleares, Spain;(20)Hospital Garcia Orcoyen, Gastroenterology Department-, Navarra, Spain;(21)Hospital Xara Assistencial Althaia, Gastroenterology, Manresa, Spain;(22)Hospital Santos Reyes-, Gastroenterology Department-, Aranda de Duero, Spain;(23)Pontevedra University Hospital Complex, Gastroenterology Department-, Pontevedra, Spain;(24)Hospital Universitari de Girona Doctor Josep Trueta, gastroenterology, Girona, Spain;(25)Hospital Infanta Elena de Valdemoro, gastroenterology, Madrid, Spain;(26)Hospital Rey Juan Carlos de Móstoles, gastroenterology, Madrid, Spain;(27)Hospital Universitario de Caceres, gastroenterology, Caceres, Spain;on behalf of the Young Group of GETECCU
P524: Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.ECCO'22Year: 2022
Authors: Riviere, P.(1);Kanters, C.(2);Ni, A.(2);Pellet, G.(1);Hupe, M.(1);Aboulhamid, N.(2);Poullenot, F.(1);Bitton, A.(2);Zerbib, F.(1);Lakatos, P.(2);Afif, W.(2);Laharie, D.(1);Bessissow, T.(2);
(1)Bordeaux University Hospital, Gastroenterology unit, Pessac, France;(2)McGill University Health Centre, Gastroenterology, Montréal, Canada;
P525: A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD studyECCO'22Year: 2022
Authors: Vavricka, S.(1);Zeitz, J.(2);Madanchi, M.(1);Biedermann, L.(1);Morsy, Y.(1);Scharl, M.(1);Gassmann, M.(3);Lutz, T.(3);Kunz, A.(4);Bron, D.(4);Rogler, G.(1);Greuter, T.(1);
(1)University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland;(2)Clinic Hirslanden Zurich, Center of Gastroenterology, Zurich, Switzerland;(3)University of Zurich, Institute of Veterinary Physiology- Vetsuisse Faculty, Zurich, Switzerland;(4)Swiss Aeromedical Center, Swiss Aeromedical Center, Dubendorf, Switzerland;
